1,193 results match your criteria Expert Review of Gastroenterology and Hepatology [Journal]


Noninvasive monitoring of hepatic steatosis: controlled attenuation parameter and magnetic resonance imaging-proton density fat fraction in patients with nonalcoholic fatty liver disease.

Expert Rev Gastroenterol Hepatol 2019 Apr 25:1-8. Epub 2019 Apr 25.

a Department of Internal Medicine , Yonsei University College of Medicine , Seoul , South Korea.

Introduction: With an increase in the worldwide prevalence of obesity, the incidence of non-alcoholic fatty liver disease (NAFLD) has been on the rise, such that it has been recently considered to be a major public health concern. Traditional interventions, such as lifestyle modifications, regular exercise, and healthy diet, have been significant in improving NAFLD with reduction of liver fat. Areas covered: Although liver biopsy is still the gold standard for diagnosis of NAFLD, there is a need for non-invasive, quantitative assessments of hepatic steatosis, especially in clinical trials of anti-steatotic medications or in the follow-up of patients undergoing lifestyle modifications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2019.1608820DOI Listing

Is teenage heavy drinking more hazardous than we thought?

Expert Rev Gastroenterol Hepatol 2019 Apr 25:1-3. Epub 2019 Apr 25.

c Stress Research Institute , Stockholm University , Stockholm , Sweden.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474124.2019.1
Publisher Site
http://dx.doi.org/10.1080/17474124.2019.1608819DOI Listing
April 2019
1 Read

Detection and management of early stage inflammatory bowel disease: an update for clinicians.

Expert Rev Gastroenterol Hepatol 2019 Apr 22:1-9. Epub 2019 Apr 22.

a IBD Center, Department of Gastroenterology , Humanitas Research Hospital , Rozzano, Milan , Italy.

Introduction: Inflammatory bowel diseases, which include Crohn's disease and ulcerative colitis, are lifetime chronic and progressive disorders of poorly known etiology. Over the past few decades, new therapeutic approaches, including early and more aggressive intervention with immunomodulators and biological agents have offered the possibility of a favorable modification in the natural history of inflammatory bowel diseases. Area covered: Here, we review the literature about the effectiveness of early detection and intervention in adult inflammatory bowel diseases patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2019.1605291DOI Listing

When a secondary form of pediatric non-alcoholic fatty liver disease should be suspected?

Expert Rev Gastroenterol Hepatol 2019 Apr 19:1-3. Epub 2019 Apr 19.

a Department of Woman, Child and General and Specialized Surgery , University of Studies of Campania "Luigi Vanvitelli" , Napoli , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2019.1605290DOI Listing

HDAC inhibitors in liver cancer: which route to take?

Expert Rev Gastroenterol Hepatol 2019 Apr 17:1-3. Epub 2019 Apr 17.

c Institute of Pathology , Paracelsus Medical University/Salzburger Landeskliniken (SALK) , Salzburg , Austria.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474124.2019.1
Publisher Site
http://dx.doi.org/10.1080/17474124.2019.1605289DOI Listing
April 2019
1 Read

Pneumococcal vaccination in celiac disease.

Expert Rev Gastroenterol Hepatol 2019 Apr 15:1-6. Epub 2019 Apr 15.

e Dipartimento Biomedico di Medicina Interna e Specialistica (DiBiMIS) , University of Palermo , Palermo , Italy.

Introduction: Celiac disease (CD) is an immune-mediated disorder associated with gluten exposure in genetically predisposed subjects. Areas covered: Infectious disease is one of the causes of morbidity and mortality in CD patients. Invasive streptococcus pneumoniae (pneumococcus) is a particularly dangerous morbid condition in both the general population and celiac patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2019.1607295DOI Listing
April 2019
4 Reads

Neo-adjuvant therapy for pancreatic cancer: hope for the future.

Expert Rev Gastroenterol Hepatol 2019 Apr 12. Epub 2019 Apr 12.

c Arizona Premier Surgery.

Introduction: In 2018, pancreatic ductal adenocarcinoma (PDAC) was the 3rd highest cause cancer related death in the United States. Worldwide estimates in 2018 indicate 458,918 cases diagnosed with 432,242 deaths. Standard therapy for decades for localized PDAC has been to pursue surgical resection for localized disease. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474124.2019.1
Publisher Site
http://dx.doi.org/10.1080/17474124.2019.1607294DOI Listing
April 2019
4 Reads

A current overview of corticosteroid use in active ulcerative colitis.

Expert Rev Gastroenterol Hepatol 2019 Apr 4:1-5. Epub 2019 Apr 4.

a Department of Internal Medicine and Gastroenterology , University of Bologna , Bologna , Italy.

Introduction: Ulcerative colitis (UC) is a chronic inflammatory condition that causes continuous mucosal inflammation of the colon. New biological drugs have been developed in order to avoid colectomy, but corticosteroids still play a crucial role in management of active UC. Areas covered: We reviewed the current literature about the importance of corticosteroid use in the treatment of ulcerative colitis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2019.1604219DOI Listing

Clinical presentations, management, and outcomes of acute esophageal necrosis: a systemic review.

Expert Rev Gastroenterol Hepatol 2019 May 16;13(5):507-514. Epub 2019 Apr 16.

a Sanford School of Medicine , University of South Dakota , Sioux Falls , SD , USA.

Background: To review all the reported literature on acute esophageal necrosis.

Research Methods: Databases were searched using the special Medical Subject Heading (MeSH) terms. All the available reported cases of acute esophageal necrosis were analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2019.1601555DOI Listing
May 2019
4 Reads

Gut microbiota: implications for radiotherapy response and radiotherapy-induced mucositis.

Expert Rev Gastroenterol Hepatol 2019 May 29;13(5):485-496. Epub 2019 Mar 29.

a Adelaide Medical School , The University of Adelaide , Adelaide , Australia.

Introduction: Radiotherapy is a mainstay of solid tumor management but can be associated with unacceptable levels of off-target tissue toxicity which impact treatment outcomes and patients' quality of life. Tumour response to radiotherapy and the frequency and severity of radiotherapy-induced toxicities, especially mucositis, varies among patients. Gut microbiota has been found to modulate both the efficacy and toxicity of some types of cancer chemotherapies and immunotherapies but has yet to be investigated thoroughly in the setting of radiotherapy. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474124.2019.1
Publisher Site
http://dx.doi.org/10.1080/17474124.2019.1595586DOI Listing
May 2019
4 Reads

Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in HIV infection: a metabolic approach of an infectious disease.

Expert Rev Gastroenterol Hepatol 2019 Mar 23:1-10. Epub 2019 Mar 23.

a Liver Research Unit , Medica Sur Clinic & Foundation , Mexico City , Mexico.

Introduction: With the successes of antiretroviral therapy, patients infected with human immunodeficiency virus (HIV) living longer. Regarding this, the common diseases of HIV population (i.e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2019.1599284DOI Listing
March 2019
1 Read
2.546 Impact Factor

Follow up on atopy and the gastrointestinal tract - a review of a common association 2018.

Expert Rev Gastroenterol Hepatol 2019 May 27;13(5):437-445. Epub 2019 Mar 27.

b School of Biomedical Sciences & Pharmacy, Faculty of Health & Medicine , University of Newcastle , Newcastle , NSW , Australia.

Introduction: Primary atopic disorders can be classified as heritable genetic disorders presenting with deregulated pathogenic allergic effector responses irrespective of sensitization. In the last decade, there are parallel rises in the burden of atopic and gastrointestinal (GI) diseases. Areas covered: There is increasing recognition of an association between atopy and GI disease through immune dysregulation, the microbiome and shared genetic pathways. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474124.2019.1
Publisher Site
http://dx.doi.org/10.1080/17474124.2019.1596025DOI Listing
May 2019
9 Reads

Advancements in the use of manometry and impedance testing for esophageal functional disorders.

Expert Rev Gastroenterol Hepatol 2019 May 21;13(5):425-435. Epub 2019 Mar 21.

b Gastrointestinal Unit, Department of Internal Medicine and Medical Specialties , University of Genoa , Genoa , Italy.

Introduction: The utilization of high-resolution manometry (HRM) has enhanced our understanding and assessment of esophageal motor disorders. Moreover, the combination of impedance technology with HRM (HRIM) has further improved our knowledge of esophageal physiology and the clinical evaluation of dysmotility, thanks to the addition of accurate measurement of bolus transit. Areas covered. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2019.1595587DOI Listing
May 2019
1 Read

Role of imaging techniques in liver veno-occlusive disease diagnosis: recent advances and literature review.

Expert Rev Gastroenterol Hepatol 2019 May 21;13(5):463-484. Epub 2019 Mar 21.

a Department of Medical and Surgical Sciences (DIMEC) , University of Bologna , Bologna , Italy.

Introduction: Veno-occlusive-disease (VOD), known also as sinusoidal-obstruction-syndrome (SOS), is one of the main complications of haematopoietic stem cell transplantation and is related to the treatment with pyrrolizidine alkaloids or other toxic agents (chemotherapy for liver-metastasis). Clinical diagnosis using the recent criteria from the European Society for Blood and Marrow Transplantation, is the reference for VOD/SOS diagnosis. However, increasing evidence suggests the emerging role of several imaging methods that could help the clinician in VOD/SOS assessment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2019.1588111DOI Listing
May 2019
2 Reads

Methotrexate for inflammatory bowel disease: time for reconsideration.

Expert Rev Gastroenterol Hepatol 2019 May 21;13(5):407-409. Epub 2019 Mar 21.

a Department of Gastroenterology, Herlev Hospital , University of Copenhagen , Herlev , Denmark.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2019.1596797DOI Listing
May 2019
1 Read

Pediatric NAFLD: an overview and recent developments in diagnostics and treatment.

Expert Rev Gastroenterol Hepatol 2019 May 4;13(5):447-461. Epub 2019 Apr 4.

a Department of Pediatric Gastroenterology and Nutrition , Amsterdam University Medical Centers, Location Academic Medical Center/Emma Children's Hospital , Amsterdam , The Netherlands.

Introduction: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in children and adults in industrialized countries. Besides liver-related morbidity, NAFLD is also associated with an increased risk of cardiovascular disease, type 2 diabetes and mortality at adult age. However, despite the high prevalence and serious complications, diagnosing and staging of disease remains complicated due to a lack of accurate screening tools and non-invasive methods to detect fibrosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2019.1595589DOI Listing
May 2019
1 Read

Circadian rhythms: a regulator of gastrointestinal health and dysfunction.

Expert Rev Gastroenterol Hepatol 2019 May 25;13(5):411-424. Epub 2019 Mar 25.

a Rush Department of Medicine, Division of Digestive Diseases and Nutrition , Rush University Medical Center , Chicago , IL , USA.

Introduction: Circadian rhythms regulate much of gastrointestinal physiology including cell proliferation, motility, digestion, absorption, and electrolyte balance. Disruption of circadian rhythms can have adverse consequences including the promotion of and/or exacerbation of a wide variety of gastrointestinal disorders and diseases. Areas covered: In this review, we evaluate some of the many gastrointestinal functions that are regulated by circadian rhythms and how dysregulation of these functions may contribute to disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2019.1595588DOI Listing
May 2019
1 Read

An update on cirrhotic cardiomyopathy.

Expert Rev Gastroenterol Hepatol 2019 May 8;13(5):497-505. Epub 2019 Mar 8.

b Gastroenterology Unit, Medical Division, Hvidovre Hospital , University of Copenhagen , Hvidovre , Denmark.

Introduction: Cirrhosis with portal hypertension and related complications are associated with a high mortality. Excess of circulating vasodilators and cardiodepressive substances lead to a hyperdynamic circulation with changed myocardial structure and function. The entity cirrhotic cardiomyopathy seems to be involved in different aspects of hepatic decompensation, which focuses on new targets of treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2019.1587293DOI Listing
May 2019
1 Read

Vitamin A and inflammatory bowel diseases: from cellular studies and animal models to human disease.

Expert Rev Gastroenterol Hepatol 2019 Jan 14;13(1):25-35. Epub 2018 Nov 14.

d School of Medicine , University of Mogi das Cruzes, Mogi das Cruzes , São Paulo , Brazil.

Introduction: Vitamin A (VA) and metabolites such as Retinoic Acid (RA) and all-trans-RA (at-RA) are crucial in the modulation of the immune system and may be determinative in the balance of the immune responses. Inflammatory bowel diseases (IBD) consist of chronic relapsing and heterogeneous disorders with not well-known etiology. Due to its role in inflammatory processes, VA may be helpful in the treatment of IBD. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474124.2019.1
Publisher Site
http://dx.doi.org/10.1080/17474124.2019.1543588DOI Listing
January 2019
4 Reads

The eradication of Helicobacter pylori to prevent gastric cancer: a critical appraisal.

Expert Rev Gastroenterol Hepatol 2019 Jan 13;13(1):17-24. Epub 2018 Nov 13.

f Department of Medicine , Michael E. DeBakey VA Medical Center, and Baylor College of Medicine , Houston , TX , USA.

Introduction: Gastric cancer is one of the top causes of cancer-related death worldwide. How to eliminate gastric cancer is an urgent public-health issue. Areas covered: In this review, we present up-to-date results of studies on gastric cancer prevention through the eradication of Helicobacter pylori and discuss strategies and obstacles for the implementation of population-wide screening and treatment of this pathogen to prevent gastric cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2019.1542299DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391731PMC
January 2019
2 Reads

Management of dysphagia in multiple sclerosis: current best practice.

Expert Rev Gastroenterol Hepatol 2019 Jan 15;13(1):47-54. Epub 2018 Nov 15.

b Department of Medical and Surgery Specialties , University of Catania , Catania , Italy.

Introduction: Multiple sclerosis (MS) is characterized by extreme variability in both severity and clinical course. It can show severe disabling symptoms, and among them dysphagia is frequently described. However, its management still represents a challenge in the daily care. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2019.1544890DOI Listing
January 2019
1 Read

Systematic review: the etiology of esophageal squamous cell carcinoma in low-income settings.

Expert Rev Gastroenterol Hepatol 2019 Jan 14;13(1):71-88. Epub 2018 Nov 14.

a Malawi Liverpool Wellcome Trust Clinical Research Programme , Blantyre , Malawi.

Introduction: Esophageal carcinoma causes over 380 000 deaths per year, ranking sixth worldwide in mortality amongst all malignancies. Globally, the squamous cell subtype is most common and accounts for 80% of esophageal cancers. Nonetheless, esophageal squamous cell carcinoma is much more poorly understood than esophageal adenocarcinoma, including what is driving such high prevalences, why it often presents in young patients, and shows such marked geographical delineations Areas covered: The current literature was searched for articles focusing on aetiopathogenesis of squamous cell esophageal carcinoma via a systematic review, particularly in low-resource settings. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2019.1543024DOI Listing
January 2019

Postprandial distress syndrome: stratification and management.

Expert Rev Gastroenterol Hepatol 2019 Jan 8;13(1):37-46. Epub 2018 Nov 8.

a Translational Research Center for Gastrointestinal Diseases (TARGID) , University of Leuven , Leuven , Belgium.

Introduction: Functional dyspepsia (FD), defined by the Rome consensus as the presence of functional symptoms originating from the gastroduodenum, is one of the most common functional gastrointestinal disorders. FD is subdivided into postprandial distress syndrome (PDS), with meal-related symptoms such as postprandial fullness and early satiation, and epigastric pain syndrome (EPS), with meal-unrelated symptoms such as epigastric pain or burning. We used a literature search for a narrative review on the current state of knowledge regarding PDS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2019.1543586DOI Listing
January 2019
1 Read

Short bowel syndrome in children and adults: from rehabilitation to transplantation.

Expert Rev Gastroenterol Hepatol 2019 Jan 31;13(1):55-70. Epub 2018 Oct 31.

b Gastroenterology Hepatology Nutrition Unit , Hôpital Necker-Enfants Malades , Paris , France.

Introduction: Short bowel syndrome (SBS) is a dramatic clinical condition in both children and adults; the residual bowel length is not sufficient to avoid intestinal failure, with subsequent malnutrition and growth retardation, and intravenous support is required to provide the nutrients normally coming from the intestine. Apart from the primary disease, the medical status can be worsened by complications of intestinal failure: if there are irreversible, the prognosis is poor unless a successful intestinal rehabilitation is achieved. Areas covered: The rescue of the remnant small bowel requires a multidisciplinary expertise to achieve digestive autonomy. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474124.2019.1
Publisher Site
http://dx.doi.org/10.1080/17474124.2019.1541736DOI Listing
January 2019
1 Read

Obesity, diabetes, and the gut microbiome: an updated review.

Expert Rev Gastroenterol Hepatol 2019 Jan 13;13(1):3-15. Epub 2018 Nov 13.

a Medically Associated Science and Technology (MAST) Program , Cedars-Sinai Medical Center , Los Angeles , CA , USA.

Introduction: Obesity and diabetes are two of the most prevalent health problems and leading causes of death globally. As research on the intestinal microbiome increases, so does our understanding of its intricate relationship to these diseases, although this has yet to be fully elucidated. Areas covered: This review evaluates the role of the gut microbiome in obesity and diabetes, including the influences of internal and environmental factors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2019.1543023DOI Listing
January 2019
1 Read

Ritonavir-boosted paritaprevir, ombitasvir plus ribavirin could improve eGFR in patients with renal impairment and HCV: an Egyptian cohort.

Expert Rev Gastroenterol Hepatol 2019 Jan 13;13(1):89-93. Epub 2018 Nov 13.

a Endemic Medicine and Hepato-gastroenterology Department, Faculty of Medicine , Cairo University , Cairo , Egypt.

Background: The present study aimed at evaluation of changes in estimated glomerular filtration rate (eGFR) among chronic Hepatitis C virus (HCV) patients with chronic kidney disease (CKD) Stages 3-5 who were treated with 12 weeks of ritonavir-boosted paritaprevir, ombitasvir plus ribavirin.

Methods: Changes in renal functions were compared across follow up time points (baseline, SVR4, and SVR8). Data on on-treatment adverse events (AEs), serious AEs, laboratory abnormalities, treatment discontinuation were collected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2019.1544070DOI Listing
January 2019
1 Read

Is treating the gut microbiome the key to achieving better outcomes in cirrhosis?

Expert Rev Gastroenterol Hepatol 2019 Jan 13;13(1):1-2. Epub 2018 Nov 13.

a Liver Sciences, School of Immunology and Microbial Science, Faculty of Life Sciences and Medicine , King's College London , London , UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2019.1543587DOI Listing
January 2019
2 Reads

Sarcopenia and chronic liver diseases.

Expert Rev Gastroenterol Hepatol 2018 Dec 16;12(12):1229-1244. Epub 2018 Oct 16.

c Graduate Institute of Clinical Medicine , National Taiwan University College of Medicine , Taipei , Taiwan.

Introduction: Sarcopenia is a syndrome characterized by progressive and generalized loss of skeletal muscle mass and strength, which is commonly associated with various chronic diseases, including chronic liver diseases. Growing lines of evidence indicate that sarcopenia not only correlates with the clinical outcomes and survival of patients undergoing liver transplant, but also serves as a prognostic factor for candidates of liver transplantation and patients with hepatocellular carcinoma. Areas covered: In this review, we conducted a narrative review and search of literature from PubMed, Ovid MEDLINE, and the Cochrane Library database up to August 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2018.1534586DOI Listing
December 2018
1 Read

Therapeutic implication of platelets in liver regeneration -hopes and hues.

Expert Rev Gastroenterol Hepatol 2018 Dec 11;12(12):1219-1228. Epub 2018 Oct 11.

a Cardiovascular and Gastroenterological Surgery, Graduate School of Medical and Dental Sciences , Kagoshima University , Kagoshima , Japan.

Introduction: Mounting evidence highlights platelet involvement in liver regeneration via interaction with liver cells, growth factors release, and signaling contributions. Existing research suggests a compelling biological rationale for utilizing platelet biology, with the goal of improving liver function and accelerating its regenerative potential. Despite its expanding application in several clinical areas, the contribution of the platelet and its therapeutic implementation in liver regeneration so far has not yet fulfilled the initial high expectations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2018.1533813DOI Listing
December 2018

Role of the biliary microbiome in gallstone disease.

Expert Rev Gastroenterol Hepatol 2018 Dec 14;12(12):1193-1205. Epub 2018 Oct 14.

a Department of Gastroenterology , The First Affiliated Hospital of Nanchang University , Nanchang, Jiangxi , China.

Introduction: Gallstone disease is caused by multiple pathogenic factors and is common worldwide. Most studies have focused on the significance of the biliary microbiome in gallstone pathogenesis. Areas covered: In this study, the epidemiology of gallstone diseases and the existence, composition, origin, and mechanisms of the biliary microbiota were reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2018.1533812DOI Listing
December 2018
1 Read

Endoscopic management of complications of acute pancreatitis: an update on the field.

Expert Rev Gastroenterol Hepatol 2018 Dec 25;12(12):1207-1218. Epub 2018 Oct 25.

a Department of Medicine A , University Medicine Greifswald , Greifswald , Germany.

Introduction: Acute pancreatitis is a frequent, nonmalignant gastrointestinal disorder leading to hospital admission. For its severe form and subsequent complications, minimally invasive and endoscopic procedures are being used increasingly, and are subject to rapid technical advances. Areas covered: Based on a systematic literature search in PubMed, medline, and Web-of-Science, we discuss the currently available treatment strategies for endoscopic therapy of pancreatic pseudocysts, walled-off pancreatic necrosis (WON), and disconnected pancreatic duct syndrome (DPDS), and compare the efficacy and safety of plastic and metal stents. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2018.1537781DOI Listing
December 2018

Cost-utility analysis of second-generation direct-acting antivirals for hepatitis C: a systematic review.

Expert Rev Gastroenterol Hepatol 2018 Dec 31;12(12):1251-1263. Epub 2018 Oct 31.

d Real-World Insights , IQVIA , Barcelona , Spain.

Introduction: High prices of second-generation direct-acting antivirals (DAAs) in the treatment of chronic hepatitis C virus (HCV) patients led to reimbursement decisions based on cost per quality-adjusted life year (QALY). Areas covered: We performed a systematic review of cost-utility analyses (CUA) comparing interventions with second-generation DAA therapies with no treatment, and with previous therapies for chronic HCV patients until July 2017. A total of 36 studies were included: 30 studies from the perspective of the healthcare payer, 3 from the societal perspective, and 3 did not report the perspective. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2018.1540929DOI Listing
December 2018

Direct acting antivirals failure: cause and retreatment options.

Expert Rev Gastroenterol Hepatol 2018 Dec 31;12(12):1245-1250. Epub 2018 Oct 31.

a Department of Hepatology , Cochin Hospital , Paris , France.

Introduction: Chronic hepatitis C (HCV) infection is a systemic life-threatening condition that can lead to hepatic and extra-hepatic complications. Sustained virological response (SVR) is associated with a regression of most liver and non-liver manifestations, which reduce mortality. The history of HCV infection therapy radically changed in the last decade, with the introduction of the first generation direct acting antivirals (DAAs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2018.1541237DOI Listing
December 2018
1 Read

Adverse events in IBD therapy: the 2018 update.

Expert Rev Gastroenterol Hepatol 2018 Dec;12(12):1183-1191

a Department of Medicine, Division of Gastroenterology and Hepatology , University of Maryland School of Medicine , Baltimore , MD , USA.

Introduction: Crohn's disease and ulcerative colitis affect an increasing number of patients, and utilization of immune suppressant and biologic therapies is also increasing. These agents are linked to adverse events ranging from mild nuisance symptoms to potentially life-threatening complications including infections and malignancies. Areas covered: This review provides an updated discussion on adverse events associated with immunomodulator, anti-TNF-α, anti-integrin, and anti-IL 12/IL-23 antibody therapies. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474124.2018.1
Publisher Site
http://dx.doi.org/10.1080/17474124.2018.1545574DOI Listing
December 2018
8 Reads

Non-alcoholic fatty liver disease and cardiovascular risk: an update.

Expert Rev Gastroenterol Hepatol 2018 Dec 16;12(12):1175-1177. Epub 2018 Oct 16.

c Reader and Honorary Consultant, Department of Clinical Biochemistry, Royal Free Hospital Campus, University College London Medical School , University College London (UCL) , London , UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2018.1533117DOI Listing
December 2018

Precision medicine beyond medical oncology: using molecular analysis to guide treatments of colorectal neoplasia.

Expert Rev Gastroenterol Hepatol 2018 Dec 17;12(12):1179-1181. Epub 2018 Oct 17.

b Head of Colorectal Surgery , Royal North Shore Hospital , Sydney , Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2018.1535897DOI Listing
December 2018

To cap/cuff or ring: do distal attachment devices improve the adenoma detection?

Expert Rev Gastroenterol Hepatol 2019 Feb 15;13(2):119-127. Epub 2018 Dec 15.

a Gastroenterology Queen Alexandra Hospital , Portsmouth , United Kingdom.

Introduction: Colonoscopy reduces the risk of colorectal cancer, by interrupting the adenoma-carcinoma sequence enabling the detection and removal of adenomas before they turn into colorectal cancer. Colonoscopy has its limitations as adenoma miss rates as high as 25% have been reported. The reasons for missed pathology are complicated and multi-factorial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2019.1551131DOI Listing
February 2019
2.546 Impact Factor

Molecular basis and cellular mechanisms of eosinophilic esophagitis for the clinical practice.

Expert Rev Gastroenterol Hepatol 2019 Feb 15;13(2):99-117. Epub 2018 Nov 15.

b Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) , Madrid , Spain.

Introduction: Eosinophilic esophagitis (EoE) is a chronic, allergen-driven inflammatory esophageal disease characterized by predominantly eosinophilic inflammation leading to esophageal dysfunction. Recent efforts to understand EoE have increased our knowledge of the disease. Areas covered: Multiple cells, molecules, and genes interplay with early life environmental factors in the pathophysiology of EoE to converge in the esophageal epithelium at the center of disease pathogenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2019.1546120DOI Listing
February 2019

Biosimilars for inflammatory bowel disease: how can healthcare professionals help address patients' concerns?

Expert Rev Gastroenterol Hepatol 2019 Feb 17;13(2):143-155. Epub 2019 Jan 17.

a Department of Gastroenterology and Hepatology , Amsterdam UMC , Amsterdam , The Netherlands.

Introduction: The patent expiration of some biologics used in chronic conditions such as inflammatory bowel disease (IBD) has led to the development of biosimilar monoclonal antibodies. The tailored regulatory approval route for biosimilar development ensures that approved biosimilars show similarity to their originators in terms of efficacy and safety, and avoids unnecessary repetition of clinical trials carried out with the originator product. However, some patients may still have concerns about using biosimilars and it is the responsibility of healthcare professionals (HCPs) to alleviate these concerns. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2019.1553617DOI Listing
February 2019
7 Reads

Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease.

Expert Rev Gastroenterol Hepatol 2019 Feb 29;13(2):179-187. Epub 2018 Dec 29.

a Medical School , University of Western Australia , Nedlands , Australia.

Introduction: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide and is associated with hepatocellular carcinoma (HCC), the most frequent malignant liver tumor. The increasing prevalence of obesity and diabetes is influencing the epidemiology of HCC with the most dramatic increases in NAFLD-related HCC seen in Western countries. Although cirrhosis is the major risk factor for HCC in NAFLD, there is increasing recognition that NAFLD-HCC occurs in the absence of cirrhosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2019.1549989DOI Listing
February 2019

Cholesterol cholelithiasis: part of a systemic metabolic disease, prone to primary prevention.

Expert Rev Gastroenterol Hepatol 2019 Feb 27;13(2):157-171. Epub 2018 Nov 27.

c Department of Biomedical Sciences and Human Oncology, Clinica Medica "A. Murri" , University of Bari Medical School , Bari , Italy.

Introduction: Cholesterol gallstone disease have relationships with various conditions linked with insulin resistance, but also with heart disease, atherosclerosis, and cancer. These associations derive from mechanisms active at a local (i.e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2019.1549988DOI Listing
February 2019
4 Reads

Follow-up on: optimizing lesion detection in small bowel capsule endoscopy and beyond: from present problems to future solutions.

Expert Rev Gastroenterol Hepatol 2019 Feb 6;13(2):129-141. Epub 2018 Dec 6.

a Department of Computer Science and Biomedical Informatics , University of Thessaly , Lamia , Greece.

Introduction: This review presents noteworthy advances in clinical and experimental Capsule Endoscopy (CE), focusing on the progress that has been reported over the last 5 years since our previous review on the subject. Areas covered: This study presents the commercially available CE platforms, as well as the advances made in optimizing the diagnostic capabilities of CE. The latter includes recent concept and prototype capsule endoscopes, medical approaches to improve diagnostic yield, and progress in software for enhancing visualization, abnormality detection, and lesion localization. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2019.1553616DOI Listing
February 2019
2.546 Impact Factor

An update on the evaluation and management of iron deficiency anemia in inflammatory bowel disease.

Expert Rev Gastroenterol Hepatol 2019 Feb 7;13(2):95-97. Epub 2018 Dec 7.

a Crohn Colitis Clinical Research Centre Rhein-Main , Frankfurt am Main , Germany.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474124.2019.1
Publisher Site
http://dx.doi.org/10.1080/17474124.2019.1553618DOI Listing
February 2019
4 Reads

Nonalcoholic steatohepatitis before and after liver transplant: keeping up with the times.

Expert Rev Gastroenterol Hepatol 2019 Feb 30;13(2):173-178. Epub 2018 Nov 30.

e Multivisceral Transplant Unit, Department of Surgery, Oncology and Gastroenterology , Padua University Hospital , Padua , Italy.

Introduction: In the last years, nonalcoholic steatohepatitis (NASH) has become a leading indication for liver transplant (LT). After transplant, both recurrent and de novo nonalcoholic fatty liver disease (NAFLD) can be commonly diagnosed. However, dedicated surveillance programs for patients with pre- or post-transplant NAFLD are not available. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2019.1551132DOI Listing
February 2019

An update on the pathogenesis and clinical management of cirrhosis with refractory ascites.

Expert Rev Gastroenterol Hepatol 2019 Apr 12;13(4):293-305. Epub 2018 Dec 12.

a Division of Gastroenterology, Department of Medicine, Toronto General Hospital , University of Toronto , Toronto , Ontario , Canada.

Introduction: Ascites commonly complicates cirrhosis, becoming refractory to treatment with diuretics and sodium restriction in approximately 10% of patients. Pathogenesis of refractory ascites (RA) is multifactorial, the common final pathway being renal hypoperfusion and avid sodium retention. Refractory ascites has a negative prognostic implication in the natural history of cirrhosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2018.1555469DOI Listing
April 2019
2 Reads

Update on C-reactive protein and fecal calprotectin: are they accurate measures of disease activity in Crohn's disease?

Expert Rev Gastroenterol Hepatol 2019 Apr 3;13(4):319-330. Epub 2019 Jan 3.

b Robarts Clinical Trials Inc ., London , Ontario , Canada.

Introduction: 'Treat-to-target' paradigms in Crohn's disease (CD) directed at suppressing intestinal inflammation require accurate and reliable measures of disease activity. Although endoscopy has traditionally been considered a gold standard, cost, complexity, resource limitations, and invasiveness are important limitations. Hence, substantial interest exists for non-invasive serum and fecal biomarkers, namely C-reactive protein (CRP) and fecal calprotectin (FC), in the diagnosis, monitoring, and treatment of CD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2019.1563481DOI Listing
April 2019
3 Reads

Irritable bowel syndrome: a review of the general aspects and the potential role of vitamin D.

Expert Rev Gastroenterol Hepatol 2019 Apr 23;13(4):345-359. Epub 2019 Jan 23.

a Medical School of Marília , UNIMAR , São Paulo , Brazil.

Introduction: Irritable Bowel Syndrome (IBS) is a bowel disorder leading to symptoms such as abdominal pain, modifications in the motility and bowel habits, distention, bloating, and gas. Vitamin D (VD) may interfere in a plethora of cellular mechanisms, and act directly or indirectly in the regulation of the microbiome, the release of anti-microbial peptides, modulation of the immune system and inflammation processes; which in turn, may positively interfere with the altered gut function. The main purpose of this review was to survey studies involving the impacts of VD on IBS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2019.1570137DOI Listing

Oxaliplatin in perioperative chemotherapy for gastric and gastroesophageal junction (GEJ) adenocarcinoma.

Expert Rev Gastroenterol Hepatol 2019 Apr 4;13(4):285-291. Epub 2019 Feb 4.

b Comprehensive Cancer Center Freiburg (CCCF) , Medical Center - University of Freiburg , Freiburg , Germany.

Introduction: Platinum-based chemotherapy remains standard-of-care for gastric and gastroesophageal junction (GEJ) adenocarcinoma. For locally advanced resectable disease, perioperative treatment with cisplatin-based doublet or triplet chemotherapy regimens had been the predominant approach in Europe and the US, based on pivotal phase III trials including the MAGIC study. Results from more recent landmark studies including the German FLOT4 and the Asian CLASSIC trials have, however, triggered a shift from cisplatin towards oxaliplatin-based chemotherapy protocols in the perioperative setting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2019.1573143DOI Listing

Extraintestinal manifestations in inflammatory bowel disease - epidemiology, genetics, and pathogenesis.

Expert Rev Gastroenterol Hepatol 2019 Apr 20;13(4):307-317. Epub 2019 Feb 20.

a Department of Gastroenterology and Hepatology , University Hospital Zurich , Zurich , Switzerland.

Introduction: Inflammatory bowel disease (IBD) is a chronic inflammatory disorder, primarily of, but not restricted to the gut. Extraintestinal manifestations (EIMs) are frequently observed and involve the joints, eyes, hepatobiliary tract, and skin. Areas covered: In this review, we discuss classical EIM focusing on epidemiology, genetics, and pathogenesis, highlighting recent advances in the understanding of EIM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2019.1574569DOI Listing
April 2019
1 Read

Non-invasive assessment of liver fibrosis and prognosis: an update on serum and elastography markers.

Expert Rev Gastroenterol Hepatol 2019 Apr 20;13(4):361-374. Epub 2019 Feb 20.

b Baylor University Medical Center , Dallas , TX , USA.

Introduction: Non-invasive assessment of fibrosis is increasingly utilized in clinical practice to diagnose hepatic fibrosis. Non-invasive assessment of liver fibrosis relies on biologic and/or physical properties to assess tissue fibrosis. Serum markers estimate fibrosis by incorporating markers reflecting hepatic function (indirect markers) and/or markers measuring extracellular matrix degradation/fibrogenesis (direct markers). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2019.1579641DOI Listing
April 2019
1 Read